Capital increase 2018

Below you find further information about the capital increase that was resolved by the Management Board of Epigenomics AG with approval of the Supervisory Board on October 7, 2018.

NOTE:
The information contained on this web page is neither an offer for sale of securities nor solicitation to buy any securities. This information is not for circulation in the United States of America (”United States”) or within the United States (including its territories and dependencies, states and the District of Columbia) and may not be forwarded or circulated to “U.S. persons” (as defined in Regulation S under the U.S. Securities Act of 1933 in its currently applicable form [“Securities Act”]) or to publications with a general circulation in the United States. The information contained on this web page is neither an offer nor a solicitation to buy any securities in the United States. The securities of Epigenomics AG have not been and will not be registered under the provisions of the Securities Act and may not be offered or sold within the United States or to U.S. persons without being registered or without the presentation of an exemption from the registration requirements. There will be no public offering of securities in the United States, the United Kingdom, Australia, Canada, Japan or South Africa.

For further information, please don’t hesitate to contact us:

Epigenomics AG
Bertha-Benz-Straße 5
10557 Berlin

Contact:
Peter Vogt
VP Corporate Communication & Investor Relations
E-Mail: ir@epigenomics.com
Tel: +49 30 243 45 – 386